Lynch Syndrome Clinical Trial
Official title:
Chromoendoscopy in Lynch Syndrome Patients
Lynch syndrome (LS), or hereditary nonpolyposis colorectal cancer (HNPCC), is a hereditary disorder predisposing for colorectal cancer. To reduce the risk of colorectal cancer, patients undergo colonoscopy every 1-2 years. Chromoendoscopy is relatively new technique which improves the detection of adenomas, the precursor lesions of colorectal cancer. The aim of this study is to determine whether chromoendoscopy, including polypectomy of all detected lesions, reduces the development of colorectal neoplasia and the need for colectomy in LS patients.
Lynch syndrome (LS), or hereditary nonpolyposis colorectal cancer (HNPCC), is an autosomally
dominantly inherited disorder that accounts for 1-2 % of colorectal cancer cases. LS is
caused by germline genomic alterations in one of the mismatch repair (MMR) genes hMLH1,
hMSH2, hMSH6 and hPMS2. The lifetime incidence of colorectal cancer is 20-75 % in these
mutation carriers. Individuals with LS-associated colorectal cancer differ from those with
sporadic disease in several ways: the tumours are diagnosed at an earlier age; the majority
of tumours is located in the proximal colon; there is an increased risk of developing
synchronous or metachronous colorectal cancers and the prognosis relatively favourable
compared to sporadic cases. It is generally accepted that LS associated colorectal cancers
develop along the adenoma-carcinoma sequence as in sporadic cases. There is evidence
suggesting that the adenoma-carcinoma sequence is accelerated in LS patients as compared to
the general population.
Colonoscopic screening and subsequent removal of polyps at a 3-year interval in asymptomatic
at-risk members of LS families has shown to reduce the incidence of colorectal cancer and
improve overall survival. However, within such an interval in surveillance programs,
interval cancers have been observed. It is therefore currently recommended that MMR gene
mutation carriers should be kept under surveillance by regular colonoscopy every 1-2 years
beginning at the age of 20-25 or 5-10 years younger than the earliest affected family
member.
LS adenomas are predominantly located in the proximal colon and frequently carry villous
architecture and high-grade dysplasia, markers that are associated with an increased risk of
developing colorectal cancer. Even in LS adenomas smaller than 5-7 mm in size, high-grade
dysplasia can be encountered. Therefore, the identification of high-risk precursor lesions
in LS is considered of paramount importance.
It is known that conventional colonoscopy has a certain miss rate for colorectal neoplasms,
especially small adenomas. A few years ago, the technique of chromoendoscopy was introduced.
Chromoendoscopy, in which one of various dyes are sprayed onto the colonic mucosa via a
spray catheter passed through the working channel of the endoscope, offers detailed
evaluation of the mucosal surface. Indigo carmine is a contrast stain that is not absorbed
and does not react with the surface mucosa. In 2 large randomised controlled trials
chromoendoscopy significantly increased the detection of small adenomas in the proximal
colon as compared to conventional colonoscopy. Recently, 2 trials in LS patients revealed
that chromoscopic endoscopy improved the detection of adenomas, particularly flat lesions,
compared to conventional colonoscopy. Together, these data suggest that chromoendoscopy may
improve detection rates of significant neoplastic colonic lesions in LS patients. However,
the true value of chromoendoscopy in the management of LS patients remains to be
demonstrated.
The aim of this study is to determine whether chromoendoscopy, including polypectomy of all
detected lesions, reduces the development of colorectal neoplasia and the need for colectomy
in LS patients at follow-up endoscopy.
The results of the study will indicate the value of chromoendoscopy in the management of LS
patients and whether the technique should be implemented in current surveillance procedures.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00217737 -
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
|
Phase 3 | |
Active, not recruiting |
NCT02194387 -
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
|
N/A | |
Recruiting |
NCT04909671 -
Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome.
|
N/A | |
Recruiting |
NCT04379999 -
Atorvastatin ± Aspirin in Lynch Syndrome Syndrome
|
Early Phase 1 | |
Recruiting |
NCT05692596 -
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
|
||
Completed |
NCT01845753 -
Molecular Screening for Lynch Syndrome in Denmark
|
||
Completed |
NCT01216930 -
Molecular Screening for Lynch Syndrome in Southern Denmark
|
N/A | |
Not yet recruiting |
NCT05963191 -
CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome
|
N/A | |
Active, not recruiting |
NCT02912559 -
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
|
Phase 3 | |
Recruiting |
NCT04978350 -
Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study
|
N/A | |
Active, not recruiting |
NCT03832985 -
Pediatric Reporting of Adult-Onset Genomic Results
|
Early Phase 1 | |
Withdrawn |
NCT04778566 -
Evaluating the Cologuard Test for Use in Lynch Syndrome
|
||
Completed |
NCT02570516 -
NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome
|
N/A | |
Completed |
NCT01823471 -
I-Scan For Colon Polyp Detection In HNPCC
|
N/A | |
Recruiting |
NCT02813824 -
Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome
|
Phase 3 | |
Recruiting |
NCT05078866 -
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT03744962 -
MSI in Circulatory DNA of Endometrial Cancer
|
||
Recruiting |
NCT04711434 -
PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients
|
Phase 3 | |
Completed |
NCT04131062 -
Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants
|
N/A | |
Recruiting |
NCT05704010 -
Videocapsule Endoscopy in Lynch Syndrome
|
N/A |